Stockscreener 앱 받기
16.30
3.62%
0.57
시장 영업 전:
16.30
Cullinan Therapeutics Inc 주식(CGEM)의 최신 뉴스
[SCHEDULE 13G] Cullinan Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
CGEM: Transformational milestones and pivotal data for autoimmune and AML programs expected by 2026 - TradingView
CGEM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Cullinan Therapeutics (CGEM) Stock Analysis: Exploring A 101% Upside Potential - DirectorsTalk Interviews
Cullinan Therapeutics (NASDAQ:CGEM) Shares Up 7.6%Here's Why - MarketBeat
Cullinan Therapeutics executives to join major healthcare conference fireside chats - Traders Union
Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $25,169.20 in Stock - MarketBeat
Insider Sell: Jennifer Michaelson Sells Shares of Cullinan Thera - GuruFocus
Cullinan Therapeutics (CGEM) CSO sells 1,780 shares in Rule 10b5-1 trade - Stock Titan
CGEM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 1,752 Shares - MarketBeat
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells 3,601 Shares of Stock - MarketBeat
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $66,301.54 in Stock - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) CEO Nadim Ahmed Sells 13,515 Shares - MarketBeat
Cullinan Therapeutics (CGEM) CSO sells 5,353 shares under 10b5-1 plan - Stock Titan
Cullinan Therapeutics (CGEM) CMO sells shares to cover RSU tax bill - Stock Titan
[Form 4] Cullinan Therapeutics, Inc. Insider Trading Activity - Stock Titan
Jennifer Michaelson sells shares under 10b5-1 (CGEM) - Stock Titan
Cullinan Therapeutics (NASDAQ:CGEM) Hits New 12-Month HighWhat's Next? - MarketBeat
Cullinan Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Cullinan Therapeutics: Thesis Strengthening For T-Cell Engager Specialist (NASDAQ:CGEM) - Seeking Alpha
Jennifer Michaelson Sells 11,742 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Insider Jeffrey Alan Jones Sells 4,982 Shares - MarketBeat
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) CFO Sells 4,398 Shares of Stock - MarketBeat
Cullinan Therapeutics (CGEM) CMO sells 4,982 shares for RSU tax obligations - Stock Titan
Cullinan Therapeutics (CGEM) CSO exercises options and sells 11,742 shares - Stock Titan
Cullinan Therapeutics (CGEM) CLO sells 3,742 shares to cover tax - Stock Titan
Cullinan Therapeutics (CGEM) CEO sells shares to cover RSU tax bill - Stock Titan
Cullinan Therapeutics (CGEM) CFO sells shares to cover RSU tax bill - Stock Titan
CGEM (NASDAQ: CGEM) Form 144 shows 1,752-share proposed resale; insider sales listed - Stock Titan
Cullinan Therapeutics Inc expected to post a loss of 81 cents a shareEarnings Preview - TradingView
Is Cullinan Therapeutics Inc. benefiting from innovation trendsCEO Change & Detailed Earnings Play Strategies - mfd.ru
Cullinan Therapeutics (NASDAQ:CGEM) Cut to Hold at Zacks Research - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Stock Rating Lowered by Zacks Research - MarketBeat
Cullinan Therapeutics, Inc. (CGEM) Investor Outlook: A Biotech With 120% Upside Potential - DirectorsTalk Interviews
Will Cullinan Therapeutics Inc. stock recover faster than peersJuly 2025 PreEarnings & Smart Money Movement Alerts - mfd.ru
What is the long term forecast for Cullinan Therapeutics Inc. stockJuly 2025 Sentiment & Detailed Earnings Play Alerts - mfd.ru
What is Cullinan Therapeutics Inc.’s valuation compared to sectorJuly 2025 Selloffs & Real-Time Stock Price Movement Reports - mfd.ru
Jennifer Michaelson proposes sale of 8,000 shares | CGEM SEC FilingForm 144 - Stock Titan
Cullinan Therapeutics (NASDAQ:CGEM) Research Coverage Started at Citigroup - Defense World
Cullinan Therapeutics Touts 2026 “Defining Year” as T-Cell Engager, Zipalertinib Catalysts Near - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Hits New 1-Year HighTime to Buy? - MarketBeat
CGEM: 2026 will bring major clinical and regulatory milestones across oncology and autoimmune programs - TradingView
Cullinan Therapeutics (NASDAQ:CGEM) Earns Buy Rating from Analysts at Citigroup - MarketBeat
Cullinan Therapeutics (CGEM) Expected to Announce Quarterly Earnings on Thursday - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit - The Globe and Mail
Cullinan leaders join Citi virtual oncology fireside chat on Feb. 19 - Stock Titan
Citigroup Initiates Coverage of Cullinan Therapeutics (CGEM) with Buy Recommendation - Nasdaq
Citigroup Initiates Buy Coverage on CGEM with $33 Target | CGEM Stock News - GuruFocus
Citigroup Initiates Cullinan Therapeutics at Buy With $33 Price Target - marketscreener.com
Can Cullinan Therapeutics Inc. ride the EV waveMarket Risk Report & Low Risk High Reward Trade Ideas - mfd.ru
CGEM PE Ratio & Valuation, Is CGEM Overvalued - Intellectia AI
US Market Wrap: What’s the RSI of Cullinan Therapeutics Inc. stockWeekly Trade Recap & High Conviction Buy Zone Picks - mfd.ru
Cullinan Therapeutics, Inc. (CGEM) Investor Outlook: Exploring A 159.97% Potential Upside - DirectorsTalk Interviews
CGEM Should I Buy - Intellectia AI
Cullinan Therapeutics Tees Up Catalyst-Heavy 2026 With Q2 CLN-978 Data and AML Fast Track Momentum - MarketBeat
CGEM: 2026 will deliver key data for T cell engagers in autoimmune and AML, driving major portfolio catalysts - TradingView
CGEM: 2026 will deliver major clinical catalysts in autoimmune and oncology, backed by strong financials - TradingView
Layoff Watch: How does SNDA perform in inflationary periodsGlobal Markets & Safe Entry Zone Identification - baoquankhu1.vn
Retail Trends: Whats the profit margin of Cullinan Therapeutics IncProduct Launch & Intraday High Probability Alerts - baoquankhu1.vn
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight - Yahoo Finance
Cullinan Therapeutics (NASDAQ:CGEM) Rating Lowered to Sell at Wall Street Zen - MarketBeat
0.11%
6.00%
자본화:
|
볼륨(24시간):